Aurinia Pharmaceuticals Inc. — Revenue by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/10d91ea3-437a-4996-84d5-8e280e780cd6/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $283.1M | 2025-01-01 – 2025-12-31 | evidence 0001600620-26-000017 |
| FY 2024 | $235.1M | 2024-01-01 – 2024-12-31 | evidence 0001600620-25-000011 |
| FY 2023 | $175.5M | 2023-01-01 – 2023-12-31 | evidence 0001600620-24-000012 |
| FY 2022 | $134.0M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-005341 |
| FY 2021 | $45.6M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-004082 |
| FY 2020 | $50.1M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-003060 |
| FY 2019 | $318.0k | 2019-01-01 – 2019-12-31 | evidence 0001628280-21-003060 |
| FY 2018 | $463.0k | 2018-01-01 – 2018-12-31 | evidence 0001628280-21-003060 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Aurinia Pharmaceuticals Inc. — all facts · Net Income · Operating Income